Navigation Links
Zosano Pharma, Inc. Appoints Nandan Oza as Chief Operations Officer
Date:5/14/2013

FREMONT, Calif., May 14, 2013 /PRNewswire/ -- Zosano Pharma, Inc., a privately held pharmaceutical company developing products based on its novel transdermal delivery technology, announced today a key addition to its executive team with the appointment of Nandan Oza as the company's Chief Operations Officer. In this position, Mr. Oza will guide the company's efforts in manufacturing, quality and engineering – vital activities to enable the company to accelerate the development of its innovative multi-product portfolio.

"I am pleased to welcome Nandan as our COO," said Vikram Lamba, Chief Executive Officer, Zosano Pharma. "His operational and manufacturing experience and expertise – as well as his leadership experience – will be critical in preparing Zosano for our next stage of commercial-scale manufacturing as we drive our clinical programs towards the marketplace."

Prior to joining Zosano Pharma, Mr. Oza served as Vice President, Chemistry, Manufacturing and Controls at Talon Therapeutics. He previously held the position of Vice President, Manufacturing and Supply Chain Operations at Jazz Pharmaceuticals and at Connetics Corporation (now a part of GSK). Mr. Oza also held positions of increasing responsibility at ALZA Pharmaceuticals (now part of Johnson and Johnson) in Product Development, Quality and Technical and Manufacturing Operations, progressing to his role as Executive Director, Bay Area Operations. Mr. Oza earned a Bachelor's degree (with honors) in Mechanical Engineering from the University of Houston, pursued graduate studies in Engineering from the University of California, Davis and earned an MBA from National University, San Diego, CA.

"This is an exciting time to join the Zosano Pharma team," said Mr. Oza. "The company is well positioned to move forward in commercial scale manufacturing with its ZP Patch Technology and advancing development-stage product pipeline."

About Zosano Pharma
Zosano Pharma, Inc. is a private biopharmaceutical company and a pioneer in the field of drug delivery systems. Zosano is developing products using ZP Patch Technology, a novel transdermal delivery technology based on microprojections that provide rapid and efficient systemic delivery in a convenient, needle–free, and pain–free system. Zosano is a fully integrated development company with a recently launched cGMP manufacturing capability. The company is developing products with significant commercial potential both independently and in collaboration with strategic partners. Learn more at http://www.zosanopharma.com.


'/>"/>
SOURCE Zosano Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.
2. Zosano Pharma, Inc. Announces Key Strategic Hire
3. DFH Pharma, USA Partners with Hetero Group, INDIA to Develop 2nd Generation HIV Maturation Inhibitor Drugs
4. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
5. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
6. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
7. InnoPharma, Inc., Announces U.S. FDA Approval of Acetylcysteine Solution, USP, 20% for Inhalation or Oral Administration
8. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
10. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
11. Optimer Pharmaceuticals Appoints Eric Sirota as Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition ... - 2035" report to their offering. ... The Deep Learning: Drug Discovery and Diagnostics ... the growing market of deep learning solutions within the healthcare domain. ... emerged as a novel solution to generate relevant insights from medical ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and ... 2015 through 2022. Also, a six-year historic analysis is provided for these ...
(Date:3/24/2017)... March 23, 2017  Mirabilis Medical, a ... technology for non-invasive surgery, announced today CE Mark ... treatment of uterine fibroids throughout the European Union.  ... approval from the US Food and Drug Administration ... System in the United States.  The Mirabilis System ...
Breaking Medicine Technology:
(Date:3/25/2017)... Kennett Square, PA (PRWEB) , ... March 25, 2017 , ... ... one priority as a public relations partner. , All through the year, Garden ... stories and press releases, working with key influencers and pitching client’s key messages ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... which will spark a conversation on the current obstacles facing infection prevention and ... completely preventable deaths caused by these infections. , The print component of ...
(Date:3/24/2017)... ... , ... According to a new study by NCPA Senior Fellow John R. ... rules Congress has directed the CBO to follow. The CBO itself previously recognized Obamacare ... it estimates a reduction in employer-based coverage due to the GOP reform, which is ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, proudly presents her ... 9--24, 2017. This sacred and spiritual journey during the Summer Solstice will ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She will ... The majority of cases litigated under ERISA involve claims for long-term disability benefits. ...
Breaking Medicine News(10 mins):